Pancreatic Growth Hormone Releasing Factor Stimulates Growth Hormone Secretion by Pituitary Cells

Adams, Eric F.; Winslow, Charmaine; Mashiter, Κ.

doi:10.1016/s0140-6736(83)91931-1

Cited by 21 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lower potency of NPY was also illustrated by its effects on GHRH-stimulated GH secretion. NPY only partially inhibited the stimulatory effects of GHRH, whereas similar or lower doses of SRIH completely block GHRH stimulation of GH secretion in vitro (Adams et al 1983. NPY did, however, reduce the effects of theophylline in a similar manner, as previously described for SRIH (Adams et al 1979(Adams et al , 1981b Adrian et al 1983;Allen et al 1983;Crowley et al 1985;DiMaggio et al 1985).…”

Section: Discussionsupporting

confidence: 66%

Neuropeptide Y directly inhibits growth hormone secretion by human pituitary somatotropic tumours

Adams¹,

Venetikou²,

Woods³

et al. 1987

Acta Endocrinologica

View full text Add to dashboard Cite

Neuropeptide Y (NPY) is a 36 amino acid peptide, widely distributed throughout the brain and is found in hypothalamic neurones. This latter finding suggests that NPY may possess a hypophysiotropic function. A number of studies have demonstrated effects of NPY on LH and GH secretion by rat pituitary cells. We report here the results of experiments investigating the effects of NPY on GH secretion by tumorous human somatotropic pituitary cells in culture. NPY (0.25\p=n-\25 nmol/l) inhibited GH secretion by 20\p=n-\53%, the maximal effect depending upon the tumour studied. The potency of NPY was less than that of somatostatin (SRIH). The stimulatory effects of growth hormone releasing factor (GHRH) and theophylline were reduced by NPY, but NPY did not modify the inhibitory effect of SRIH on GH secretion. It is concluded that NPY may be involved in the control of GH secretion, at least by tumorous human pituitary somatotropes.

show abstract

Section: Discussionsupporting

confidence: 66%

Neuropeptide Y directly inhibits growth hormone secretion by human pituitary somatotropic tumours

Adams¹,

Venetikou²,

Woods³

et al. 1987

Acta Endocrinologica

View full text Add to dashboard Cite

show abstract

“…In addition, hypothalamic tumors containing GHRH have been associated with sparsely granulated somatotroph adenomas (162). In vitro, human somatotroph adenoma cells are known to respond to GHRH stimulation (167)(168)(169)(170)(171)(172), indicating the presence of GHRH receptors on these tumors, but they are known to lack the downregulation characteristic of normal somatotrophs (170,171). In vitro, human somatotroph adenoma cells are known to respond to GHRH stimulation (167)(168)(169)(170)(171)(172), indicating the presence of GHRH receptors on these tumors, but they are known to lack the downregulation characteristic of normal somatotrophs (170,171).…”

mentioning

confidence: 99%

The Cytogenesis and Pathogenesis of Pituitary Adenomas*

1998

View full text Add to dashboard Cite

“…105,120 Intra-pituitary GHRH expression is well documented, 59,76,95 and GHRH may be overexpressed in some aggressive tumors. 119 In vitro, human somatotroph adenomas respond to GHRH stimulation 3,4,62,80,114,125 consistent with functional GHRH receptors on these tumors. In some instances, however, they may lose the down-regulation characteristic of normal somatotrophs.…”

Section: Hormone Receptorsmentioning

confidence: 71%

The Pathophysiology of Pituitary Tumors

Ezzat¹,

Sylvia²

2002

Seminars in Neurosurgery

View full text Add to dashboard Cite

Numerous factors have been shown to govern pituitary cell proliferation; these various hypophysiotropic hormones and growth factors (GFs) likely play a role as promoters of tumor cell growth in genetically transformed cells. The clonal composition of pituitary adenomas attests to the molecular basis of pituitary tumorigenesis; however, the oncogenes and tumor suppressor genes that are implicated in the transformation events for the vast majority of pituitary tumors remain unknown. Mutations that have been identified in other human malignancies are restricted to a very small subset of pituitary neoplasms implicating novel genetic and/or epigenetic alterations. This review details some of the currently known alterations of GFs and their receptors that have been implicated in pituitary tumorigenesis. Some of the epigenetic changes noted in nuclear components that govern cell cycle control are also reviewed. The emerging knowledge from these studies is shedding new light not only on the pathogenesis of pituitary tumors but on novel mechanisms in the broader context of human neoplasia.Objectives: On completion of this article, the reader should understand the mechanisms involved in the development of pituitary tumors and the differences between experimental models and the primary human pituitary adenomas.

show abstract

Pancreatic Growth Hormone Releasing Factor Stimulates Growth Hormone Secretion by Pituitary Cells

Cited by 21 publications

References 11 publications

Neuropeptide Y directly inhibits growth hormone secretion by human pituitary somatotropic tumours

Neuropeptide Y directly inhibits growth hormone secretion by human pituitary somatotropic tumours

The Cytogenesis and Pathogenesis of Pituitary Adenomas*

The Pathophysiology of Pituitary Tumors

Contact Info

Product

Resources

About